RxDoctor Payments Data

Amy Beckman, DO

Family Medicine · Erie, PANPI 1780244111

Payments from drug & device makers

$3,482in general payments, 2019–2025

Across 130 payments — averaging $26.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Exact Sciences$1K
  • AstraZeneca$492
  • Novo Nordisk$422
  • Lilly USA, LLC$299
  • Amgen$213
  • Medtronic$211
  • plus $789 from 21 others

What the payments were for

  • Food & beverage$3,482100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,482 in reported general payments places this provider in the 80th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$19,979
Medicare patients
50
Services billed
342

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide34$52,989
XareltoRivaroxaban63$40,965
Trelegy ElliptaFluticasone/Umeclidin/Vilanter41$31,051
TrulicityDulaglutide33$31,038
EliquisApixaban29$27,854
JardianceEmpagliflozin21$20,476
LinzessLinaclotide18$19,480
RybelsusSemaglutide13$12,387
JanuviaSitagliptin Phosphate15$11,248
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$10,279
Breo ElliptaFluticasone/Vilanterol20$9,790
Stiolto RespimatTiotropium Br/Olodaterol Hcl14$6,607
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$5,202
Gabapentin181$3,876
Mesalamine ErMesalamine13$3,077

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$422$65,37647 claims
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$122$43,58174 claims
Johnson & JohnsonXarelto$29$40,96563 claims
Lilly USA, LLCTrulicity$299$31,03833 claims
PfizerEliquis$59$27,85429 claims
Boehringer IngelheimJardiance, Stiolto Respimat$61$27,08335 claims
AbbVieLinzess, Synthroid$67$20,80645 claims
AstraZenecaBreztri Aerosphere$492$10,27914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Erie

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →